uniQure N.V. (QURE) Stock Analysis & Winston Score

uniQure is a Dutch biotechnology company that develops gene therapies — treatments designed to fix or replace broken genes inside a patient's body. Its most advanced product is Hemgenix, a one-time gene therapy for hemophilia B, a rare blood disorder where patients cannot stop bleeding properly. Hemgenix was approved by the FDA in 2022 and is one of the most expensive medicines ever sold, priced at around $3.5 million per dose. The company earns money through product sales of Hemgenix and through licensing deals and royalties with partners like CSL Behring, which handles commercialization of Hemgenix in the US and globally. uniQure operates primarily in the Netherlands and the United States and is a small-cap company still spending heavily on research, which explains its deeply negative operating margin. Its pipeline includes gene therapies for Huntington's disease and other rare conditions, but the key risk is that gene therapy adoption remains slow due to the extreme cost and limited patient populations.